PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
AUPH vs. NXTC
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between AUPH and NXTC is 0.27, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.3

Performance

AUPH vs. NXTC - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Aurinia Pharmaceuticals Inc. (AUPH) and NextCure, Inc. (NXTC). The values are adjusted to include any dividend payments, if applicable.

-100.00%-50.00%0.00%50.00%SeptemberOctoberNovemberDecember2025February
26.67%
-96.20%
AUPH
NXTC

Key characteristics

Sharpe Ratio

AUPH:

0.00

NXTC:

-0.55

Sortino Ratio

AUPH:

0.37

NXTC:

-0.49

Omega Ratio

AUPH:

1.05

NXTC:

0.94

Calmar Ratio

AUPH:

0.00

NXTC:

-0.43

Martin Ratio

AUPH:

0.01

NXTC:

-0.97

Ulcer Index

AUPH:

25.29%

NXTC:

44.18%

Daily Std Dev

AUPH:

50.57%

NXTC:

77.46%

Max Drawdown

AUPH:

-87.58%

NXTC:

-99.25%

Current Drawdown

AUPH:

-76.45%

NXTC:

-99.18%

Fundamentals

Market Cap

AUPH:

$1.12B

NXTC:

$21.21M

EPS

AUPH:

-$0.15

NXTC:

-$2.19

Total Revenue (TTM)

AUPH:

$175.27M

NXTC:

$0.00

Gross Profit (TTM)

AUPH:

$152.57M

NXTC:

-$1.64M

EBITDA (TTM)

AUPH:

$21.43M

NXTC:

-$42.56M

Returns By Period

In the year-to-date period, AUPH achieves a -13.25% return, which is significantly lower than NXTC's -1.82% return.


AUPH

YTD

-13.25%

1M

-2.75%

6M

24.44%

1Y

33.16%

5Y*

-16.98%

10Y*

8.13%

NXTC

YTD

-1.82%

1M

-4.06%

6M

-51.47%

1Y

-48.15%

5Y*

-56.56%

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

AUPH vs. NXTC — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

AUPH
The Risk-Adjusted Performance Rank of AUPH is 4343
Overall Rank
The Sharpe Ratio Rank of AUPH is 4444
Sharpe Ratio Rank
The Sortino Ratio Rank of AUPH is 4141
Sortino Ratio Rank
The Omega Ratio Rank of AUPH is 4141
Omega Ratio Rank
The Calmar Ratio Rank of AUPH is 4545
Calmar Ratio Rank
The Martin Ratio Rank of AUPH is 4545
Martin Ratio Rank

NXTC
The Risk-Adjusted Performance Rank of NXTC is 2020
Overall Rank
The Sharpe Ratio Rank of NXTC is 1717
Sharpe Ratio Rank
The Sortino Ratio Rank of NXTC is 1919
Sortino Ratio Rank
The Omega Ratio Rank of NXTC is 2121
Omega Ratio Rank
The Calmar Ratio Rank of NXTC is 2020
Calmar Ratio Rank
The Martin Ratio Rank of NXTC is 2323
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

AUPH vs. NXTC - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Aurinia Pharmaceuticals Inc. (AUPH) and NextCure, Inc. (NXTC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for AUPH, currently valued at 0.00, compared to the broader market-2.000.002.004.000.00-0.55
The chart of Sortino ratio for AUPH, currently valued at 0.37, compared to the broader market-6.00-4.00-2.000.002.004.006.000.37-0.49
The chart of Omega ratio for AUPH, currently valued at 1.05, compared to the broader market0.501.001.502.001.050.94
The chart of Calmar ratio for AUPH, currently valued at 0.00, compared to the broader market0.002.004.006.000.00-0.43
The chart of Martin ratio for AUPH, currently valued at 0.01, compared to the broader market-10.000.0010.0020.0030.000.01-0.97
AUPH
NXTC

The current AUPH Sharpe Ratio is 0.00, which is higher than the NXTC Sharpe Ratio of -0.55. The chart below compares the historical Sharpe Ratios of AUPH and NXTC, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-0.60-0.40-0.200.000.200.40SeptemberOctoberNovemberDecember2025February
0.00
-0.55
AUPH
NXTC

Dividends

AUPH vs. NXTC - Dividend Comparison

Neither AUPH nor NXTC has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

AUPH vs. NXTC - Drawdown Comparison

The maximum AUPH drawdown since its inception was -87.58%, smaller than the maximum NXTC drawdown of -99.25%. Use the drawdown chart below to compare losses from any high point for AUPH and NXTC. For additional features, visit the drawdowns tool.


-100.00%-95.00%-90.00%-85.00%-80.00%-75.00%-70.00%-65.00%SeptemberOctoberNovemberDecember2025February
-76.45%
-99.18%
AUPH
NXTC

Volatility

AUPH vs. NXTC - Volatility Comparison

The current volatility for Aurinia Pharmaceuticals Inc. (AUPH) is 11.12%, while NextCure, Inc. (NXTC) has a volatility of 16.14%. This indicates that AUPH experiences smaller price fluctuations and is considered to be less risky than NXTC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%15.00%20.00%25.00%SeptemberOctoberNovemberDecember2025February
11.12%
16.14%
AUPH
NXTC

Financials

AUPH vs. NXTC - Financials Comparison

This section allows you to compare key financial metrics between Aurinia Pharmaceuticals Inc. and NextCure, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab